CoChat

Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population

Open access
Romley, John A., Goldman, Dana P., Solomon, Matthew, McFadden, Daniel, Peters, Anne L. · 2012 · Diabetes Technology & Therapeutics
Cited by 85

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Postmarketing reports have linked exenatide use with acute pancreatitis and pancreatic cancer, but a definitive relationship has yet to be established. SUBJECTS AND METHODS: We conducted a retrospective cohort analysis of patients with type 2 diabetes with employer-provided health insurance from 2007 to 2009. Multivariate models estimated the association between exenatide use and acute pancreatitis and pancreatic cancer. We required at least 1 year of exenatide exposure in the pancreatic cancer analysis. Sensitivity analyses were conducted that quasirandomized exenatide use based on patient out-of-pocket costs. RESULTS: Among 268,561 patients included in the acute pancreatitis analysis, only 2.6% used exenatide. Hospitalization for acute pancreatitis was rare (0.247% of patients). In unadjusted and adjusted analyses, patients who did not use exenatide were more likely to be hospitalized for acute pancreatitis (0.249% vs. 0.196% in unadjusted analysis), but the difference was not statistically significant in either analysis (P = 0.22 and P = 0.70, respectively). Among 209,306 patients in the pancreatic cancer analysis, 0.070% were diagnosed with pancreatic cancer, and 0.88% had at least 1 year of continuous exenatide exposure prior to the diagnosis. Those with exenatide exposure had higher rates of pancreatic cancer compared with those without (0.081% vs. 0.070% in unadjusted analysis). In both unadjusted and adjusted analyses, the difference was not statistically significant (P = 0.80 and P = 0.46, respectively). In sensitivity analyses, results were similar. CONCLUSIONS: We found no association between exenatide use and either hospitalization for acute pancreatitis or pancreatic cancer in a large sample of privately insured U.S. patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/dia.2012.0075

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

    Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 4×

    “By examining the most recent administrative data available (2009), our analysis examines a time period that is equivalent to the only published analysis that broadly examines exenatide’s pancreatic cancer risk.(10) Furthermore, for patients who took 365 days or more of exenatide prior to the year of incident cancer di…”
    BackgroundMethodResultInfluential
  • Exenatide (Exendin-4)–Induced Pancreatitis

    Denker, P. S., & Dimarco, P. E. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-2043 · Cited by 140 · cited 1×

    “However, postmarketing reports of acute pancreatitis, including severe forms such as hemorrhagic or necrotizing pancreatitis, developing in patients taking exenatide were submitted to the Food and Drug Administration (FDA)(1,2) and have been published in the literature.(3,4) Although these reports do not prove a causa…”
    Background
  • Exenatide-Induced Acute Pancreatitis

    Ayoub, W. A., Kumar, A. A., Naguib, H. S., & Taylor, H. C. (2010) · Endocrine Practice · doi:10.4158/ep09104.crr · Cited by 58 · cited 1×

    “However, postmarketing reports of acute pancreatitis, including severe forms such as hemorrhagic or necrotizing pancreatitis, developing in patients taking exenatide were submitted to the Food and Drug Administration (FDA)(1,2) and have been published in the literature.(3,4) Although these reports do not prove a causa…”
    Background

Show all 3 references

Cited by

Metadata

Authors
Romley, J. A., Goldman, D. P., Solomon, M., McFadden, D., & Peters, A. L.
Venue
Diabetes Technology & Therapeutics
Published
2012-10
Volume
14
Issue
10
Pages
904-911
ISSN
  • 1520-9156 (ISSN-L)
  • 1557-8593
OpenAlex
W2066987382
Cited by
85
References
3
FWCI
8.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.